Display options
Cite
Ozawa PM, Ariza CB, Losi-Guembarovski R, et al. Wilms' tumor susceptibility: possible involvement of FOXP3 and CXCL12 genes. Mol Cell Pediatr. 2016;3(1):36doi: 10.1186/s40348-016-0064-4.
Ozawa, P. M., Ariza, C. B., Losi-Guembarovski, R., Guembarovski, A. L., de Oliveira, C. E., Banin-Hirata, B. K., Kishima, M. O., Petenuci, D. L., & Watanabe, M. A. (2016). Wilms' tumor susceptibility: possible involvement of FOXP3 and CXCL12 genes. Molecular and cellular pediatrics, 3(1), 36. https://doi.org/10.1186/s40348-016-0064-4
Ozawa, Patricia Midori Murobushi, et al. "Wilms' tumor susceptibility: possible involvement of FOXP3 and CXCL12 genes." Molecular and cellular pediatrics vol. 3,1 (2016): 36. doi: https://doi.org/10.1186/s40348-016-0064-4
Ozawa PM, Ariza CB, Losi-Guembarovski R, Guembarovski AL, de Oliveira CE, Banin-Hirata BK, Kishima MO, Petenuci DL, Watanabe MA. Wilms' tumor susceptibility: possible involvement of FOXP3 and CXCL12 genes. Mol Cell Pediatr. 2016 Dec;3(1):36. doi: 10.1186/s40348-016-0064-4. Epub 2016 Nov 10. PMID: 27830498; PMCID: PMC5103003.
Copy Download .nbib Format: NLM
Share it on

Mol Cell Pediatr. 2016 Dec;3(1):36. doi: 10.1186/s40348-016-0064-4. Epub 2016 Nov 10.

Wilms' tumor susceptibility: possible involvement of FOXP3 and CXCL12 genes.

Molecular and cellular pediatrics

Patricia Midori Murobushi Ozawa, Carolina Batista Ariza, Roberta Losi-Guembarovski, Alda Losi Guembarovski, Carlos Eduardo Coral de Oliveira, Bruna Karina Banin-Hirata, Marina Okuyama Kishima, Diego Lima Petenuci, Maria Angelica Ehara Watanabe

Affiliations

  1. Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Londrina, PR, Brazil.
  2. Department of Pathology, Clinical Analysis and Toxicology, Health Sciences Center, State University of Londrina, Londrina, PR, Brazil.
  3. Department of Pathological Sciences, Laboratory of Study and Application of DNA Polymorphisms, Biological Sciences Center, State University of Londrina, Londrina, PR, Brazil. [email protected].

PMID: 27830498 PMCID: PMC5103003 DOI: 10.1186/s40348-016-0064-4

Abstract

BACKGROUND: Wilms' tumor is an embryonal neoplasm of the kidney that accounts for approximately 6 % of all childhood tumors. The chemokine CXCL12 (C-X-C chemokine ligand 12) and its ligand CXCR4 (C-X-C chemokine receptor type 4) are involved in the development of several organs, including the kidney, and are also associated with tumor growth and metastasis. FOXP3 (forkhead transcription factor 3) was initially described as a marker for regulatory T cells; however, its expression in several types of tumor cells has already been described and may have prognostic significance. The aim of the present study was to analyze rs3761548 and rs2232365 FOXP3 polymorphisms, as well as evaluate rs1801157 CXCL12 polymorphism in Wilms' tumor samples.

METHODS: Polymorphisms were evaluated in 32 patients and 78 neoplasia-free controls. Genotypes of rs1801157 were determined using PCR-restriction fragment length polymorphism (PCR-RFLP) method, and genotypes of rs2232365 and rs3761548 were determined using allele-specific PCR (AS-PCR).

RESULTS: The case-control study indicated a significant association for allele A carriers of rs1801157 polymorphism in relation to Wilms' tumor susceptibility (OR = 5.261; 95 % CI 2.156 to 12.84; p = 0.0002). The opposite was observed in male carriers of G allele for rs2232365 polymorphism (OR 0.1164; 95 % CI 0.0227 to 0.5954; p = 0.0091) or when male and female subjects were analyzed (OR = 0.1304; 95 % CI 0.05013 to 0.3394; p < 0.0001).

CONCLUSIONS: All in all, these markers may contribute to this neoplasia susceptibility and progression; however, further studies are needed to real clarify their role in Wilms' tumor pathogenesis.

Keywords: CXCL12; FOXP3; Genetic polymorphism; Wilms’ tumor

References

  1. Curr Top Microbiol Immunol. 2011;344:1-24 - PubMed
  2. Biomed Res Int. 2014;2014:341654 - PubMed
  3. Nat Med. 2006 Sep;12 (9):1081-7 - PubMed
  4. Mol Clin Oncol. 2013 Jul;1(4):625-632 - PubMed
  5. Annu Rev Pharmacol Toxicol. 2008;48:171-97 - PubMed
  6. Cancer Res. 2007 Sep 1;67(17):8344-50 - PubMed
  7. Nat Immunol. 2003 Apr;4(4):330-6 - PubMed
  8. J Pathol. 2014 Sep;234(1):74-85 - PubMed
  9. J Dermatol Sci. 2010 Jan;57(1):51-6 - PubMed
  10. Am J Pathol. 2002 Jun;160(6):2181-90 - PubMed
  11. J Clin Lab Anal. 2009;23(6):387-93 - PubMed
  12. Microcirculation. 2003 Jun;10(3-4):359-70 - PubMed
  13. Cancer Res. 2011 Mar 15;71(6):2162-71 - PubMed
  14. Cell. 2007 Jun 29;129(7):1275-86 - PubMed
  15. Adv Pediatr. 2012;59(1):247-67 - PubMed
  16. J Am Soc Nephrol. 2002 Apr;13(4):957-67 - PubMed
  17. Semin Immunol. 1998 Jun;10(3):179-85 - PubMed
  18. Cell Res. 2006 Jan;16(1):3-10 - PubMed
  19. Crit Rev Oncog. 2009;15(1-2):43-63 - PubMed
  20. Dev Dyn. 2009 May;238(5):1083-91 - PubMed
  21. Clin Cancer Res. 2007 Sep 1;13(17):5056-62 - PubMed
  22. Cancer Res. 2008 Apr 15;68(8):3001-9 - PubMed
  23. Clin Exp Med. 2013 Aug;13(3):211-9 - PubMed
  24. Nat Rev Immunol. 2004 Nov;4(11):889-99 - PubMed
  25. Nature. 2001 Mar 1;410(6824):50-6 - PubMed
  26. Nat Rev Immunol. 2006 Apr;6(4):295-307 - PubMed
  27. Science. 2003 Feb 14;299(5609):1057-61 - PubMed
  28. Semin Immunol. 2003 Feb;15(1):49-55 - PubMed
  29. Clin Dev Immunol. 2012;2012:896458 - PubMed
  30. J Am Soc Nephrol. 2009 Aug;20(8):1714-23 - PubMed
  31. Oncogene. 2005 Jan 13;24(3):457-68 - PubMed
  32. Breast Cancer Res. 2007;9(4):212 - PubMed
  33. Pediatr Blood Cancer. 2006 Sep;47(3):260-7 - PubMed
  34. Tissue Antigens. 2007 Jul;70(1):1-11 - PubMed
  35. J Clin Lab Anal. 2007;21(1):49-54 - PubMed
  36. Br J Dermatol. 2013 Sep;169(3):571-8 - PubMed
  37. Science. 1998 Jan 16;279(5349):389-93 - PubMed
  38. Development. 2001 Jun;128(11):1971-81 - PubMed
  39. Cell. 2005 May 6;121(3):335-48 - PubMed
  40. J Transl Med. 2008 Apr 22;6:19 - PubMed
  41. Mol Biol Rep. 2013 Jul;40(7):4591-6 - PubMed

Publication Types